Mortality and Renal Outcomes Are Impacted by Obesity in Cardiorenal Metabolic Disease but Not in People with Concomitant Diabetes Mellitus.

IF 2.4 4区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Cardiorenal Medicine Pub Date : 2024-01-01 Epub Date: 2023-12-29 DOI:10.1159/000536038
Saif Al-Chalabi, Rajkumar Chinnadurai, Philip A Kalra, Smeeta Sinha
{"title":"Mortality and Renal Outcomes Are Impacted by Obesity in Cardiorenal Metabolic Disease but Not in People with Concomitant Diabetes Mellitus.","authors":"Saif Al-Chalabi, Rajkumar Chinnadurai, Philip A Kalra, Smeeta Sinha","doi":"10.1159/000536038","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Mounting evidence in the literature describes a reverse association, whereby obesity may have a protective effect on mortality - the \"obesity paradox.\" Due to the significant overlap between elements of cardiorenal metabolic disease, we examined the effects of obesity on outcomes in a cohort of patients with non-dialysis chronic kidney disease (ND-CKD) by grouping patients according to their level of cardiometabolic co-morbidity to reduce the risk of bias.</p><p><strong>Methods: </strong>This study was undertaken on all patients with a documented body mass index (BMI) in the Salford Kidney Study database from October 2002 until December 2016. Patients were grouped according to their BMI into normal weight, overweight, and obese, and also according to their level of co-morbidity into 4 groups: group 1 had CKD only; group 2 had CKD and heart failure (HF); group 3 had CKD and diabetes mellitus (DM); and group 4 had CKD, DM, and HF. Univariate and multivariate Cox regression analyses were performed.</p><p><strong>Results: </strong>A total of 2,416 patients were included in the analysis. The median age was 67.3 years, 61.8% were male, and 96.4% were Caucasian. Obesity was associated with a lower incidence of combined outcomes in patients with ND-CKD who did not have DM (hazard ratio [HR] 0.74; p = &lt;0.001 and HR 0.48; p = 0.008 for CKD alone and CKD + HF groups, respectively). This protective effect remained significant after correcting for major factors. In patients with ND-CKD and DM, there was no difference in all-cause mortality between the normal weight group and the obesity groups.</p><p><strong>Conclusion: </strong>Obesity may be protective against adverse outcomes only in groups 1 (CKD alone) and 2 (CKD + HF). This \"protective\" effect was not seen in patients who had concomitant diabetes. These data suggest that diabetes is a potent predictor of adverse outcomes, irrespective of BMI; however, in patients without diabetes, obesity may play a protective role.</p>","PeriodicalId":9584,"journal":{"name":"Cardiorenal Medicine","volume":" ","pages":"23-33"},"PeriodicalIF":2.4000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiorenal Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000536038","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/12/29 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Mounting evidence in the literature describes a reverse association, whereby obesity may have a protective effect on mortality - the "obesity paradox." Due to the significant overlap between elements of cardiorenal metabolic disease, we examined the effects of obesity on outcomes in a cohort of patients with non-dialysis chronic kidney disease (ND-CKD) by grouping patients according to their level of cardiometabolic co-morbidity to reduce the risk of bias.

Methods: This study was undertaken on all patients with a documented body mass index (BMI) in the Salford Kidney Study database from October 2002 until December 2016. Patients were grouped according to their BMI into normal weight, overweight, and obese, and also according to their level of co-morbidity into 4 groups: group 1 had CKD only; group 2 had CKD and heart failure (HF); group 3 had CKD and diabetes mellitus (DM); and group 4 had CKD, DM, and HF. Univariate and multivariate Cox regression analyses were performed.

Results: A total of 2,416 patients were included in the analysis. The median age was 67.3 years, 61.8% were male, and 96.4% were Caucasian. Obesity was associated with a lower incidence of combined outcomes in patients with ND-CKD who did not have DM (hazard ratio [HR] 0.74; p = <0.001 and HR 0.48; p = 0.008 for CKD alone and CKD + HF groups, respectively). This protective effect remained significant after correcting for major factors. In patients with ND-CKD and DM, there was no difference in all-cause mortality between the normal weight group and the obesity groups.

Conclusion: Obesity may be protective against adverse outcomes only in groups 1 (CKD alone) and 2 (CKD + HF). This "protective" effect was not seen in patients who had concomitant diabetes. These data suggest that diabetes is a potent predictor of adverse outcomes, irrespective of BMI; however, in patients without diabetes, obesity may play a protective role.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
肥胖会影响心肾代谢疾病患者的死亡率和肾脏预后,但不会影响合并糖尿病患者的死亡率和肾脏预后。
导言:文献中越来越多的证据表明,肥胖可能会对死亡率产生保护作用,这就是 "肥胖悖论"。由于心肾代谢疾病的各种因素之间存在明显的重叠,我们对非透析性慢性肾脏病(ND-CKD)患者队列中的肥胖症对预后的影响进行了研究,并根据患者的心血管代谢并发症程度进行了分组,以降低偏倚风险:这项研究的对象是索尔福德肾脏研究数据库中 2002 年 10 月至 2016 年 12 月期间有体质指数 (BMI) 记录的所有患者。根据体重指数将患者分为正常体重、超重和肥胖三组,并根据合并疾病的程度分为四组:第一组仅患有慢性肾脏病;第二组患有慢性肾脏病和心力衰竭(HF);第三组患有慢性肾脏病和糖尿病;第四组患有慢性肾脏病、糖尿病和心力衰竭。进行了单变量和多变量考克斯回归分析:共有 2416 名患者被纳入分析。中位年龄为 67.3 岁,61.8% 为男性,96.4% 为白种人。肥胖与未患 DM 的 ND-CKD 患者较低的综合结果发生率相关(HR 0.74; p=结论:肥胖可能对不良后果具有保护作用:肥胖可能仅对第 1 组(单纯慢性肾功能衰竭)和第 2 组(慢性肾功能衰竭 + 高血压)的不良预后具有保护作用。这种 "保护 "作用在合并糖尿病的患者中并不存在。这些数据表明,无论体重指数如何,糖尿病都是不良预后的有力预测因素,然而,对于没有糖尿病的患者,肥胖可能起到保护作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Cardiorenal Medicine
Cardiorenal Medicine CARDIAC & CARDIOVASCULAR SYSTEMS-UROLOGY & NEPHROLOGY
CiteScore
5.40
自引率
2.60%
发文量
25
审稿时长
>12 weeks
期刊介绍: The journal ''Cardiorenal Medicine'' explores the mechanisms by which obesity and other metabolic abnormalities promote the pathogenesis and progression of heart and kidney disease (cardiorenal metabolic syndrome). It provides an interdisciplinary platform for the advancement of research and clinical practice, focussing on translational issues.
期刊最新文献
A New Era in the Management of Cardiorenal Syndrome: The Importance of Cardiorenal Units. Association of Liver Fibrosis Markers with Mortality Outcomes in Patients with Chronic Kidney Disease and Coronary Artery Disease: Insights from the NHANES 1999-2018 Data. EMCREG-International Multidisciplinary Consensus Panel on Management of Hyperkalemia in Chronic Kidney Disease (CKD) and Heart Failure. Cardiorenal disease and heart failure with preserved ejection fraction: Two sides of the same coin. Changes in Antigen Carbohydrate 125 in Patients Receiving Dapagliflozin Following an Admission for Acute Heart Failure.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1